Effect of Vibrator Use on Symptoms of Urgency Urinary Incontinence, Sexual Function, and Sleep (BLISS)
調査の概要
詳細な説明
This is a randomized superiority trial designed to evaluate the efficacy of scheduled vibrator use as an adjunct to standard lifestyle and behavioral modifications for urgency urinary incontinence (UUI) or urgency-predominant mixed urinary incontinence (MUI). UUI is defined as involuntary urine leakage preceded by a sudden, compelling urge to void. This will be identified and confirmed by patient report and screening with urgency-related items on the Urogenital Distress Inventory-6 (UDI-6), with participants required to report urgency-related leakage at least once per week.
Eligible participants will be recruited from the Albany Medical Center Urogynecology clinic during routine outpatient visits. After informed consent and baseline assessment, participants will be randomized 1:1 to either (1) lifestyle and bladder training counseling alone (control arm) or (2) lifestyle and bladder training counseling plus scheduled vibrator use (intervention arm). Participants in the intervention group will be instructed to use a provided FDA-registered Class II wellness vibrator for 5-10 minutes at least three times per week over an eight-week period, while all participants will receive standardized bladder retraining education materials. The primary outcome measure will be change in UDI-6 score, Female Sexual Function Index (FSFI), and Brief Pittsburgh Sleep Quality Index (B-PSQI) from baseline to eight weeks. Secondary outcomes will include validated assessments of quality of life and distress, including the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), Patient Global Impression of Improvement (PGI-I), Patient Health Questionnaire-4 (PHQ-4).
The study will be conducted at Albany Medical Center, Department of Obstetrics and Gynecology, Division of Urogynecology and Pelvic Reconstructive Surgery, following approval by the Institutional Review Board (IRB).
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Vinita Gottipati, MD
- 電話番号：518-262-5013
- メール：gottipv@amc.edu
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Assigned female at birth.
- Age ≥18 years.
- Able to read and speak English.
- Diagnosis of urgency urinary incontinence or mixed urinary incontinence (based on clinical assessment and UDI-6 urgency questions).
- Leaks urine at least once per week due to urgency.
- Postvoid residual volume <100 mL or a third of the voided volume
Exclusion Criteria:
- Pelvic organ prolapse beyond the hymen
- Neurogenic bladder, multiple sclerosis, or other neurologic causes of incontinence.
- Recurrent urinary tract infection (>3 UTIs in the past year or >2 in the past 6 months).
- Active urinary tract infection at the time of enrollment.
- Interstitial cystitis/bladder pain syndrome.
- Current use of sacral neuromodulation or percutaneous tibial nerve stimulation (PTNS).
- Bladder Botox injection within the past 6 months.
- Vibrator use within the past 3 months.
- Patients uncomfortable with vibrator use
- Pregnancy or plans for pregnancy during the study period.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Lifestyle and behavioral modifications
|
Guideline based standard lifestyle and behavioral modifications for urgency urinary incontinence
|
|
実験的：Scheduled vibrator use
Standard behavioral modifications and vibrator use
|
Guideline based standard lifestyle and behavioral modifications for urgency urinary incontinence
Scheduled vibrator use
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in score on UDI-6 from baseline to follow-up in 8 weeks.
時間枠：12 weeks
|
Submitted
|
12 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Female Sexual Function Index (FSFI)
時間枠：12 weeks
|
The Female Sexual Function Index is a 19-item questionnaire assessing domains of sexual function including desire, arousal, lubrication, orgasm, satisfaction, and pain.
Scores range from 2 to 36, with higher scores indicating better sexual function and lower likelihood of dysfunction.
|
12 weeks
|
|
Brief Pittsburgh Sleep Quality Index (B-PSQI)
時間枠：12 weeks
|
The Brief Pittsburgh Sleep Quality Index is a shortened version of the Pittsburgh Sleep Quality Index that evaluates sleep quality and disturbances over a recent time period.
Scores typically range from 0 to 15 (depending on version), with higher scores indicating worse sleep quality.
|
12 weeks
|
|
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)
時間枠：12 weeks
|
The PISQ-IR assesses sexual function in women with pelvic floor disorders and includes separate scoring for sexually active and non-sexually active individuals.
Scores vary by domain, but are generally transformed to a 0-100 scale, with higher scores indicating better sexual function and condition-specific quality of life.
|
12 weeks
|
|
Patient Global Impression of Improvement (PGI-I)
時間枠：12 weeks
|
The Patient Global Impression of Improvement is a single-item scale that asks patients to rate their condition after treatment compared to baseline.
It ranges from 1 (very much better) to 7 (very much worse), with lower scores indicating better outcomes/improvement.
|
12 weeks
|
|
Patient Health Questionnaire-4 (PHQ-4)
時間枠：12 weeks
|
The Patient Health Questionnaire-4 is an ultra-brief screening tool combining 2 items for anxiety and 2 for depression.
Scores range from 0 to 12, with higher scores indicating greater psychological distress.
|
12 weeks
|
|
International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
時間枠：12 weeks
|
The International Consultation on Incontinence Questionnaire-Short Form evaluates the frequency, severity, and impact of urinary incontinence on quality of life.
Scores range from 0 to 21, with higher scores indicating more severe symptoms and worse quality of life impact.
|
12 weeks
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Behavioral modificationの臨床試験
-
Semra TUNCAY YILMAZSemra TUNCAY YILMAZ完了
-
Square2 Systems, Inc.National Institute on Drug Abuse (NIDA)積極的、募集していない
-
University of Maryland, College ParkUniversity of Maryland, Baltimore; Henry Ford Health System完了物質関連障害 | オピオイド使用障害 | 治療遵守 | オピオイドの使用 | ケアの保持 | オピオイド中毒 | オピオイド投薬支援治療アメリカ
-
University of Maryland, College ParkUniversity of Maryland, Baltimore; National Center for Complementary and Integrative Health...完了物質使用 | 物質使用障害 | オピオイド使用障害 | ケアの保持 | メタドン治療 | ピア配信 | オピオイド使用障害（MOUD）の投薬 | 行動活性化アメリカ